REPL - Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating
2025-09-20 09:21:41 ET
The last time I spoke about Replimune ( REPL ) it was with respect to a Seeking Alpha article entitled " Replimune: Scope Goes Beyond That of RP1 Oncolytic Targeting For Melanoma . " With respect to this article, I noted the company's opportunity to potentially receive Accelerated Approval of its therapy RP1 in combination with Opdivo [nivolumab] for the treatment of patients with advanced melanoma. As an update since that article, the company did not receive U.S. marketing approval of RP1....
Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating